Sitemap

Pages

• About
  • Our history
  • Our Leadership team
  • Sustainability
  • Who are we?
• Accueil
• Career
• Co-development
• Code of conduct
• Confidentiality
• Contact us
• Development
• Diagnostic testing using Blow-Fill-Seal
• Download Center
• Events
• Galenic development
• Homepage
• Innovation
  • Curecall start-up
  • Diagnostic – Diluents & Reagents
  • Euroject® – Injection
  • Sol-Gel™ – Ophthalmology
  • Uniflash®
  • Uniflash®: Needle-free injection
• Join us
• Join Us Home
• Legal disclaimer
• Manufacturing
• News
• Newsletter
• Our services
• Our sites
• Out-licensing
• Production of commercial batches
• Products
  • Product list
• Purchasing Policy
• Purchasing Policy
• Regulatory expertise
• Season’s Greetings!
• Short Technology Presentation
• Sitemap
• Technologies
  • Blow-Fill-Seal (BFS)
  • Liquid Stick-Packs
  • Pharmaceutical Bottles
  • Preservative-free multidose (PFMD)
  • Spray
  • Suppositories & Pessaries
  • Tablets & Capsules
• Unither in a few figures

Articles

Corporate

• 30 year anniversary
• Nanjing’s R&D cell inauguration
• Foundation stone laid for Laboratoire Unither Amiens new building
• Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil.  
• Jean-François Hilaire: newly appointed CEO of Unither Pharmaceuticals
• Laboratoire Unither Coutances inaugurates its new premises and production facilities
• Unither Satisfaction Survey – 2021
• Blow-Fill-Seal (BFS) advanced aseptic process
• Team captain of Unither Industries in Gannat
• 2020 Satisfaction Survey Results
• How Unither Pharmaceuticals fights the current COVID-19 outbreak

News

• Join us at Europharm SMC
• Manufacturing of registration batches of PXT3003 in single unit doses
• What makes us proud?
• Anticipating Customer Growth
• World Sight Day
• LDPE study
• Investing in production capacity
• Unither Développement Bordeaux new Landing Page
• Pharnext moves production of its pending drug PXT303 to the United States
• The Management led by Eric Goupil gathers a consortium to acquire Unither Pharmaceuticals from Ardian
• Mouthwash stick-packs
• Official launch of the CURECALL solution to ophthalmologists in France!
• New in corneal transplant rejection: the ANSM issues an authorisation for the first industrial eye drop based on ciclosporin 2%.
• Physiological serum, Rhinovirus and Sars-COV2
• Therapeutic and environmental benefits of the nebulized form in inhaled therapy for respiratory diseases
• A BUSINESS DEVELOPER’S MISSION AT UNITHER – TO PROVIDE CUSTOMER SATISFACTION
• UNITHER invests 68 million euros in the innovative project: Euroject®
• Ophthalmic Development
• Innovative Ophthalmic products
• Self-medication: towards a new age of responsible health
• Synergism between oral paracetamol and nefopam in a murine model of postoperative pain
• Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)
• Preservative-free multidose: a disruptive technology that guarantees the absence of preservatives
• The Liquid Stick-Pack by Unither Pharmaceuticals
• Pharmaceutical Post Publication on our Sol-Gel innovation
• Pain: opioids, acetaminophen… new forms to improve their use
• Acquisition in China
• CDMO’s Challenges for Developing Oral Suspensions for Children
• Using Differentiated Drug-Delivery Technologies to Deliver Competitive Advantages
• Sol-Gel technology
• A new safer, more practical and trendy packaging: the liquid stick-pack
• Sterile single doses: Blow-Fill-Seal (BFS), an ophthalmic  technology
• Sterile single dose and limitation of contamination risks
• Galenic innovations and roads of the future
• Galenic innovations to meet the challenges of the future (Part 2)
• Hiding taste: a treatment compliance asset
• Paediatric medication ideal for avoiding false passages
• Adaptability: a vital condition

Presse

Uncategorized

• Laboratoire Kôl Olisens® eye drops, manufactured by Unither Pharmaceuticals